|

Encorafenib Clinical Trials

12 actively recruiting trials across 4 locations

▼ -1 trial since May 2026

Also known as: Braftovi, LGX 818, LGX-818, LGX818

Pipeline

Phase 1: 2Phase 2: 6Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Pierre Fabre Pharma GmbH2
  • M.D. Anderson Cancer Center2
  • Vall d'Hebron Institute of Oncology1
  • University of Utah1
  • UNICANCER1

Indications

  • Cancer12
  • Metastatic Melanoma3
  • Metastatic Colorectal Cancer3
  • Pathologic Stage IV Cutaneous Melanoma AJCC v82
  • Clinical Stage IV Cutaneous Melanoma AJCC v82

Other6 trials

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Combination Therapy for BRAF-V600E Metastatic CRCm
Phase 2
Melanoma Metastasized to the Brain and Steroids
Phase 2
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2

Iowa City, Iowa2 trials

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

University of Iowa

Phase 1/2
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

University of Iowa

Phase 1

Houston, Texas2 trials

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

M D Anderson Cancer Center

Phase 2
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

M D Anderson Cancer Center

Phase 1

Birmingham, Alabama1 trial

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

University of Alabama at Birmingham Cancer Center

Phase 2

Bethesda, Maryland1 trial

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.